Janethe De Oliveira Pena
Chief Medical Officer & Co Founder Oorja Bio
Dr. Janethe de Oliveira Pena is Chief Medical Officer at Oorja Bio and a clinical development leader with deep expertise across pulmonary hypertension, interstitial lung disease, and systemic sclerosis. She previously led the landmark sotatercept program at Acceleron and Merck, advancing it from Phase 2 through Phase 3. Prior to this, she held senior leadership roles at Bayer and Acceleron, driving global clinical programs in cardiopulmonary diseases. With a strong foundation in immunology and translational science, she has extensive experience navigating complex regulatory pathways and advancing innovative therapies for serious respiratory and fibrotic conditions.
Seminars
Thursday 1st October 2026
From Concept to Clinic: Advancing Novel Mechanisms & Regenerative Approaches in IPF as an Emerging Biotech
2:00 pm
- Sharing the journey of progressing a novel therapeutic concept into the clinic in IPF as a startup, including key scientific, operational, and funding challenges faced when building a program in a high-risk, high-reward disease area
- Exploring the shift beyond traditional antifibrotic approaches toward repair and regeneration-focused strategies, and the critical considerations when developing therapies targeting novel, and not yet widely validated, mechanisms
- Translating cross-disease learnings into IPF clinical development, including how prior experience in other respiratory indications has informed trial design, endpoint selection, and strategies to demonstrate early signals of efficacy
